RenaSci offers a range of assays that can be used to develop compounds to treat schizophrenia and related disorders. Compounds can be evaluated in well-established dopaminergic or hypoglutamatergic hyperactivity assays. They can also be assessed in the conditioned avoidance assay; selective disruption of the conditioned response is a characteristic property of both typical and novel antipsychotic agents.
- Amphetamine or PCP induced locomotor activity.
- Antipsychotic drugs reverse the hyperactivity induced by amphetamine or PCP in mice and rats
Reversal of PCP-induced hyperactivity in mice by olanzapine
- Conditioned Avoidance Response – Typical and novel antipsychotic agents selectively inhibit the conditioned response in rats without affecting the unconditioned response. The efficacy of a drug to suppress conditioned avoidance responding in rats correlates with its ability to reduce psychosis in man. The conditioned avoidance response test is a crucial model in development of drugs to treat schizophrenia
- DOI-induced head twitch in mice: many novel antipsychotic agents inhibit DOI-induced head twitch indicating an interaction with the serotonergic system
Inhibition of DOI-induced head twitch in mice by olanzapine
- Drug-induced catalepsy in rodents is an assay predictive of extrapyramidal side effects in man
Haloperidol-induced catalepsy in rats
- Weight gain is a serious side-effect of antipsychotic treatment. We have developed a rat model of antipsychotic weight gain
Effect of olanzapine on various parameters in female
rats maintained on high fat diet
- Increased plasma prolactin is a side-effect of antipsychotic drugs. We offer a plasma prolactin assay that can assess whether novel drugs to treat schizophrenia increase circulating levels of prolactin
Contact us for further information on our animal models of schizophrenia, and our assays to evaluate the side-effects of antipsychotic drugs.